Navigation Links
Solid Second Quarter 2013 for Gerresheimer
Date:7/9/2013

DUESSELDORF, Germany, July 10, 2013 /PRNewswire/ --

  • Second-quarter revenues up 4.2% to EUR 327.1m
  • Adjusted EBITDA of EUR 59.8m slightly above prior-year quarter (up 0.5%)
  • Adjusted net income at EUR 21.5m (up 0.9%)
  • Adjusted earnings per share on a par with prior-year quarter, at EUR 0.63
  • Guidance for financial year 2013 made more specific

Gerresheimer AG, one of the leading partners to the pharma and healthcare industry worldwide, generated solid figures in the second quarter of the 2013 financial year."Our strategy is geared to sustained, profitable growth.We continue to be successful in implementing that strategy.In the second quarter, we saw notable growth particularly in our medical systems for drug delivery and in pharmaceutical plastic packaging.Our latest acquisitions in India are also developing very well," said Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer increased revenues in the second quarter of financial year 2013 (financial year from December 1 to November 30) by 4.2% to EUR 327.1m. The revenue growth mainly reflects strong business in the Plastic Systems Division with pharmaceutical primary packaging, insulin pens and inhalers. Triveni, an Indian company specializing in pharmaceutical plastic packaging acquired in December 2012, likewise contributed to the increase in revenues. The Moulded Glass Division generated healthy growth rates notably with the sale of cosmetic glass packaging.

Gerresheimer recorded adjusted EBITDA of EUR 59.8m in the second quarter of 2013, an increase of 0.5% on the prior-year quarter. The adjusted EBITDA margin was 18.3%, below the 19.0% margin in the comparative period. The main causes of the decreased margin comprised the anticipated high cost of improving the production of prefillable syringes at a German plant and quality problems in the manufacture of glass ampoules identified at a Mexican plant during the second quarter.

Adjusted net income for the second quarter came to EUR 21.5m, 0.9% more than in the prior-year quarter (EUR 21.3m). Adjusted earnings per share were exactly on a par with the prior-year quarter, at EUR 0.63. Gerresheimer's capital expenditure in the second quarter of 2013 was EUR 33.4m, EUR 2.0m more than a year earlier.

Outlook

For financial year 2013, Gerresheimer continues to expect revenue growth of 5% to 6% at constant exchange rates. For adjusted EBITDA, the company has made its guidance more specific with a range of between EUR 245m and EUR 250m. Attainment of the revenue growth guidance of 5% to 6% would correspond to a potential adjusted EBITDA margin range of approximately 19.0% to 19.4%. Largely due to the healthy growth prospects in the Plastic Systems Division, capital expenditure in financial year 2013 will represent some 9% to 10% of exchange rate adjusted revenues.

- Cross reference: The press release including Group Key Figures is available at http://ots.de/AyUB2 -

The online annual report is available at: http://annualreport2012.gerresheimer.com

Contact:
Jens Kürten
Director Corporate Communication & Marketing
Phone: +49-211-6181-250
Fax:   +49-211-6181-241
E-Mail: j.kuerten@gerresheimer.com
Internet: http://www.gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Confluent Translations Consolidates Marketing Efforts
2. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
3. Sunset World will Consolidate its Presence in the Mexican Caribbean in 2013
4. Researchers nanoweld by applying light to aligned nanorods in solid materials
5. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
6. NSG Precision Leads Industry with Solid-State Nano-Deposition Calibration Standards
7. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
8. China Cord Blood Corporation to Further Consolidate its Corporate Structure
9. A KAIST research team has developed a high performance flexible solid state battery
10. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
11. Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... company reports the Company,s CEO  was featured in ... Accelerators Enter When VCs Fear To Tread: ... Leader magazine is an essential business ... everything from emerging biotechs to Big Pharmas. Their ...
(Date:4/28/2016)... NY (PRWEB) , ... April 28, 2016 , ... ... has made significant investments in recruiting top industry experts, and expanding its LATAM ... which provides industry-leading tools for clients to manage their clinical trial projects. , ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... of cannabis testing technology at the Spring 2016 Marijuana Business Conference and Expo. ... pesticides, residual solvents, heavy metals, and more. Expo attendees can stop by booth ...
(Date:4/27/2016)... VANCOUVER, British Columbia , April 27, 2016 ... "Gesellschaft" oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... sie im Anschluss an ihre Pressemitteilung vom 13. ... Inc. erhalten hat, ihre Finanzen um zusätzliche 200.000.000 ... auf 4.000.000 Kanadische Dollar zu bringen. Davon wurden ...
Breaking Biology Technology:
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/10/2016)... March 10, 2016 --> ... research report "Identity and Access Management Market by Component ... and Governance), by Organization Size, by Deployment, by Vertical, ... by MarketsandMarkets, The market is estimated to grow from ... by 2020, at a Compound Annual Growth Rate (CAGR) ...
Breaking Biology News(10 mins):